PF-8380   Click here for help

GtoPdb Ligand ID: 9142

Synonyms: compound 21 [PMID: 26745766] | compound 4 [PMID: 23300119] | PF8380
PDB Ligand
Compound class: Synthetic organic
Comment: PF-8380 is reported as a novel autotaxin inhibitor [4] for use as a tool compound for investigating the in vivo role of autotaxin and LPA in inflammation and in cancer [2,4]. An ATX inhibitor compound named PF-8380 is claimed in patent WO2011151461 [1], but this has a different chemical structure from the entity we depict here and whch was disclosed in St-Coeur et al.'s primary publication [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

PF-8380 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 95.85
Molecular weight 477.09
XLogP 3.11
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Clc1cc(COC(=O)N2CCN(CC2)CCC(=O)c2ccc3c(c2)oc(=O)[nH]3)cc(c1)Cl
Isomeric SMILES Clc1cc(COC(=O)N2CCN(CC2)CCC(=O)c2ccc3c(c2)oc(=O)[nH]3)cc(c1)Cl
InChI InChI=1S/C22H21Cl2N3O5/c23-16-9-14(10-17(24)12-16)13-31-22(30)27-7-5-26(6-8-27)4-3-19(28)15-1-2-18-20(11-15)32-21(29)25-18/h1-2,9-12H,3-8,13H2,(H,25,29)
InChI Key JMSUDQYHPSNBSN-UHFFFAOYSA-N
References
1. Aidinis V. (2011)
Autotaxin pathway modulation and uses thereof.
Patent number: WO2011151461 A2. Assignee: B.S.R.C. "Alexander Fleming". Priority date: 04/06/2010. Publication date: 08/12/2011.
2. Castagna D, Budd DC, Macdonald SJ, Jamieson C, Watson AJ. (2016)
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
J Med Chem, 59 (12): 5604-21. [PMID:26745766]
3. Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S et al.. (2010)
A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
J Pharmacol Exp Ther, 334 (1): 310-7. [PMID:20392816]
4. St-Cœur PD, Ferguson D, Morin Jr P, Touaibia M. (2013)
PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability.
Arch Pharm (Weinheim), 346 (2): 91-7. [PMID:23300119]